GH1 and Langerhans cell histiocytosis: In this context, we aimed to evaluate whether GH replacement was safe in LCH patients with GHD and whether GH replacement response (measured by serum insulin-like growth factor-1 (IGF-1) concentration, waist circumference, lipids, glucose, and QoL in this group differed from patients with two other infiltrative diseases, granulomatous and lymphocytic hypophysitis.